Shian-Ying Sung
TEL：04-24730022#11019
EMAIL：ssung@csmu.edu.tw
OFFICE：正心樓13樓校長室
A. Personal Statement
My laboratory has been at the forefront of developing innovative biomarkers derived from the tumor microenvironment to advance targeted therapies and precision medicine. While our primary focus has been on urological cancers such as prostate and bladder cancer, our research also includes other malignancies, including breast cancer. Our work is dedicated to identifying reactive stromal factors that play critical roles in cancer progression, such as stress responses, cellular migration, and invasion.
I possess extensive expertise in translational and precision medicine, and my contributions to cancer biology and biomarker discovery have been both innovative and impactful. In 2014, my laboratory partnered with the Taipei Medical University Prostate Cancer Translational Research Team. This collaboration has enhanced our understanding of the factors driving castration-resistant prostate cancer and metastatic progression and has been crucial in translating our laboratory findings into clinically actionable biomarkers and novel therapeutic targets.
Alongside our domestic collaborations, I have developed strong international partnerships with leading institutions, including Kobe University, Teikyo University (Japan), UC Davis, Case Western Reserve University, UT Southwestern University Medical Center, UT M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, and Emory University (USA). These alliances have enabled a vibrant exchange of ideas and resources, leading to numerous high-impact publications highlighting the strength of global scientific collaboration.
Recently, our laboratory has broadened its focus to include pediatric brain tumors, such as glioblastoma multiforme (GBM), atypical teratoid/rhabdoid tumors (AT/RT), and teratomas. To address these rare and challenging tumors, we have led the development of patient-derived organoid cultures, which allow us to investigate and validate the specific mechanisms driving tumor progression in pediatric patients. This innovative approach deepens our understanding of these complex malignancies and paves the way for creating targeted therapeutic strategies tailored to young patients.
B. Positions and Honors
Present Vice President, Chung Shan Medical University
Present Professor, Institute of Medicine, Chung Shan Medical University
Present Director, Office of Human Research Development, Chung Shan Medical University Hospital
Present Professor, International Ph.D. Program for Translational Science, Taipei Medical University
2021-2024 Dean, Office of Human Research, Taipei Medical University
2019-2021 Vice Dean, Office of Human Research, Taipei Medical University
2018-2019 Director, Join Clinical Research Center, Office of Human Research, Taipei Medical University, Taipei, Taiwan.
2015-2018 Deputy Director, Joint Clinical Research Center, Office of Human Research, Taipei Medical University, Taipei, Taiwan
2014-2015 Associate Director, Joint Clinical Research Center, Office of Human Research, Taipei Medical University, Taipei, Taiwan
2013-2021 Associate Professor, The Ph.D. Program for Translational Medicine, College of Med. Science and Technology, Taipei Medical University, Taipei, Taiwan
2012-2013 Associate Professor, Grad. Inst. of Cancer Biol., China Medical Univ. School of Medicine, Taichung, Taiwan
2007- 2012 Assistant Professor, Grad. Inst. of Cancer Biol., China Medical Univ. School of Medicine, Taichung, Taiwan
2006-2007 Assistant Professor, Depts. of Urology & Radiation Oncology, Emory University School of Medicine, Atlanta, GA USA
2002-2006 Lab Manager, Depts. of Urology, Emory University School of Medicine, Atlanta, GA USA.
Professional Memberships
2014-Present Active Member, Society of Basic Urological Research, AUA
2006-present Active Member, American Association of Cancer Research
2004-2006 Associate Member, American Association of Cancer Research
Honors, Awards and significant professional activities
2007 Poster Award, 1st International Cancer Symposium, Taiwan
2007 Taiwan Urology Association Outstanding Research Award
2007 Selected presentation in mini-symposium section of AACR Annual Meeting
2004 SBUR Young Investigator Travel Award
2000 Post-doctoral Fellowship Award, Virginia Commonwealth University
1999 Graduate Study Award, Virginia Commonwealth University
1999 Microbiology and Immunology Travel Award, Dept. of Microbiol. & Immunol. MCV at VCU
Current Teaching (Primary Teacher only)
Cancer Biology and Prostate Cancer
Clinical Trial Management
C. Contributions to Science (Past 5-Year)
1. Jotatsu Y, Arbiser JL, Moriwaki M, Hirata Y, Takeda S, Takada I, Chen KC, Sung SY, Shigemura K. (2024, Oct.) Dibenxolium induces apoptosis and inhibits epithelial-msenchymal transition (EMT) in bladder cancer cell cline, Scientific Reports, 14(1): 25501.
2. LN Giang, KS Wu, WC Lee, SS Chu, AD Do, MH Huang, YL Lin, CL Hsieh, SY Sung, Y Yen, TT Wong, CC Chang. (2024 Oct.) RRM2 inhibition alters cell cycle through ATM/Rb/D2F1 pathway in atypical teratoid rhabdoid tumor. Neoplasia, 58: 101075.
3. CL Hsieh, AD Do, CY Hsueh, MO Raboshakga, TN Thanh, TT Tai, HJ Kung, SY Sung*. (2024, Oct.) L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells. The Prostate, 84(11): 1434-1447.
4. Y Jotatsu, SY Sung, MH Wu, S Takeda, Y Hirata, K Maeda, SB Fang, KC Chen, K Shigemura (2024, Jun). An antibody of the secreted isoform of Disintegrin and Metalloprotease 9 (sADAM9) inhibits Epithelial-Mesenchymal Transition and migration of prostate cancer cell lines. International J. Molecular Science, 25(12): 6646.
5. AD Do, KS Wu, SS Chu, LH Giang, YL Lin, CC Chang, TT Wong, CL Hsieh, SY Sung*. (2024, Apr.) LOXL1-AS1 contributes to metastasis in sonic-hedgehog medulloblastoma by promoting cancer stem-line phenotypes. J. of Experimental & Clinical Cancer Research, 43: 130.
6. LH Giang, KS Wu, WC Le, SS Chu, AD Do, CA Change, HM Tran, TH Hsieh, HH Chen, CL Hsieh, SY Sung, AL Yu, Y Yen, TT Wong, CC Chang. (2023, Dec). Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. J. Experimental & Clinical Research, 42(1): 346.
7. Lee GH, Sung SY, Chang WN, Kao TT, TU HC, Hsiao TH, Safo MK, Fu TF (2023, Oct.) Correction: Zebrafish larvae exposed to ginkgotoxin exhibit seizure-like behavior that is relieved by pyridoxal-5’-phophate, GABA and anti-epiletic drug. Dis Model Mech, 16(10): dmm05055.
8. Maeda K, Shigemura K, Fang SB, Yang YM, Chiang YT, Sung SY, Chen KC, Nakano Y, Miyara T, Fujisawa M. A comparison of the COVID-19 pandemic on urological surgeries in Japan and Taiwan. Int. J. Urol. 2023 Jan; 30(1): 43-49.
9. Chang AC, Lin LW, Chen YM, Chen PC, Liu SC, Tai HC, Wu HC, Sung SY, Lin TH, Tang CH. The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. Int. J. Biol. Sci. 2023 Jan 1; 19(1): 760-771.
10. Tanimoto H, Shigemura K, Osawa K, Kado M, Onishi R, Fang SB, Sung SY, Miyara T, Fujisawa M. Comparative genetic analysis of the antimicrobial susceptibilities and virulence of hypermucoviscous and non-hypermucoviscous ESBL-producing Klebsiella pneumoniae in Japan. J. Microbiol Immunol Infect. 2023 Feb; 56(1): 93-103.
11. Tsai YT, Li CY, Huang YH, Chang TS, Lin CY, Chuang CH, Wang CY, Anuraga G, Chang TH, Shih TC, Lin ZY, Chen YL, Chung I, Lee KH, Chang CC, Sung SY, Yang KH, Tsui WL, Yap CV, Wu MH. Galetin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts. Oncogene. 2022 May; 41(21):3011-3023.
12. Yang YM, Shigemura K, Onishi R, Maeda K, Sung SY, Chen KC, Arakawa S, Fujisawa M. Correlation between changes in Syphilis treatment and Jarish-Herxheimer reaction. Kobe J. Med. Sci. 2022 Jan 13; 67(4): E137-E142.
13. Le TT, Hsieh CL, Lin IH, Chu CY, Do AD, Chen SH, Shigemura K, Kitagawa K, Fujisawa M, Liu MC, Chen KC, Sung SY*. The ADAM9/UBN2/AKR1C2 axis promotes resistance to androgen-deprivation in prostate cancer. Am. J. Cancer Res. 2022 Jan 15; 12(1): 176-197.
14. Wu KS, Sung SY, Huang MH, Lin YL, Chang CC, Fang CL, Wong TT, Chen HH, Tsai ML. Clinical and molecular features in medulloblastomas subtypes in children in a cohort in Taiwan. Cancer (Basel). 2022 Nov. 3; 14(21): 5419.
15. Wu KS, Jian TY, Sung SY, Hsieh CL, Huang MH, Fang CL, Wong TT, Lin YL. Enrichment of tumor-infiltrating B cells in group 4 medulloblastoma in children. Int. J. Mol. Sci. 2022 May 9; 23(9): 5287.
16. Hayashi F, Shigemura K, Maeda K, Hiraoka A, Maeshige N, Ooya T, Sung SY, Yang YM, Fujisawa M. Combined treatment with ultrasound and immune checkpoint inhibitors for prostate cancer. J. Clin. Med. 2022 Apr. 27; 11(9): 2448.
17. Moriwaki M, Le TT, Sung SY, Jotatsu Y, Yang Y, Hirata Y, Ishii A, Chiang YU, Chen KC, Shigemura K, Fujisawa M. Relevance of a disintegrin and metalloproteinase domain-containing (ADAM)9 protein expression to bladder cancer malignancy. Biomolecules. 2022 Jun 6; 12(6): 791.
18. Kurniawati I, Liu MC, Hsieh CL, Do AD, Sung SY. Targeting castration-resistant prostate cancer using mesenchymal stem cell exosome for therapeutic microRNA-let-7c delivery. Frong. Biosci (Landmark ED). 2022 Sep 6; 27(9): 256.
19. Miura M, Shigemura K, Osawa K, Nakanishi N, Nomoto R, Onishi R, Yoshida H, Sawamura T, Fang SB, Chiang YT, Sung SY, Chen KC, Miyara T, Fujisawa M. Genetic characteristics of azithromycin-resistant Neisseria gonorrhoeae collection in Hyogo, Japan during 2015-2019. J. Med. Microbiol. 2022 Jun; 71(6).
20. Hsu TW, Chen HA, Liao PH, Su YH, Chiu CF, Huang CY, Lin YJ, Hung CC, Yeh MH, Sung SY*, Su CM*. Dicer-mediated mir-200b expression contributes to cell migratory/invasive abilities and cancer stem cells properties of breast cancer cells. Aging (Albany NY). 2022 Aug 8; 14(16): 6520-6536.
21. Onishi R, Shigemura K, Osawa K, Yang YM, Maeda K, Tanimoto H, Kado M, Fang SB, Sung SY, Miyara T, Fujisawa M. Impact on quinolone resistance of plasmid-mediated quinolone resistance gene and mutations in quinolone resistance-determining regions in extended spectrum beta lactamase-producing Klebsiella pneumoniae isolated from urinary tract infection patients. Pathog. Dis. 2022 Aug 17; 80(1): ftac030.
22. Tsai ML, Lin HC Yen CH, Ku JT, Sung SY*, Chang H*. Increased risk of Tourette syndrome with leukotriene modifier using in children with allergic diseases and asthma: a nationwide population-based study. Children (Basel). 2022 Oct 22; 9(11): 1607.
23. Do AD, Kurniawati I, Hsieh CL, Wong TT, Lin YL, Sung SY*. Application of Mesenchymal Stem Cells in Targeted Delivery to the Brain: Potential and challenges of the Extracellular Vesicle-Based Approach for Brain Tumor Treatment. Int. J. Mol. Sci. 2021 Oct 17; 22(20):11187.
24. Onishi R, Shigemura K, Osawa K, Yang YM, Maeda K, Fang SB, Sung SY, Onuma K, Uda A, Miyara T, Fujisawa M. The antimicrobial resistance characteristics of imipenem-Non-susceptible, imipenemase-6-producing Escherichia coli. Antibiotics (Basel). 2021 Dec 28; 11(1): 32.
25. Huang SS, Liao WY, Hsu CC, Chan TS, Liao TY, Yang PM, Chen LT, Sung SY, Tsai KK. A novel invadopodia-specific marker for invasive and pro-metastatic cancer stem cells. Front. Oncol. 2021 May 31; 11:638311.
26. Liang KH, Chang CC, Wu KS, Yu AL, Sung SY, Lee YY, Liang ML, Chen HH, Fen JJ, Chao ME, Liao YT, Wong TT. Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis. Sci. Rep. 2021 Dec 2; 11(1): 23282.
27. Su CM, Hsu TW, Sung SY, Huang MT, Chen KC, Huang CY, Chiang CY, Su YH, Chen HA, Liao PH. AXL is crucial for E1A-enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through HFI in breast cancer. Environ. Toxicol. 2021 Jul; 36(7): 1278-1287.
28. Chen BW, Chiu GW, He YC, Huang CY, Huang HT, Sung SY, Hsieh CL, Chang WC, Hsu WS, Wei ZH, Yao DJ. Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid. PLoS One 2021 Feb 5; 16(2):0245286.
29. Sung SY, Le TTH, Chen JH, Hsieh TF, Hsieh CL. Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan. PLoS One 2020 Nov 19; 15(11): e0242429.
30. Chiang YT, Shigemura K, Nishimoto K, Yamada N, Kitagawa K, Sung SY, Chen KC, Fujisawa M. Urinary Track Infection Pathogens and Antimicrobioal Susceptibilities in Kobe, Japan and Taipei, Taiwan: an International analysis. J. Int. Med. Res. 2020 Feb; 48(2): 300060519867826.
31. Chen BW, He YC, Sung SY, Le TTH, Hsieh CL, Chen JY, Wei ZH, Yao DJ. Synthesis and characterization of magnetic nanoparticles coated with polystyrene sulfonic acid for biomedical applications. Sci. Technol. Adv. Mater. 2020 Jul 22; 21(1): 471-481.
32. Ishii A, Shigemura K, Kitagawa K Sung SY, Chen KC, Chiang YT, Liu MC, Fujisawa M. Anti-tumor effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-Resistant Prostate Cancer. Anticancer Res. 2020 Sep; 40(9):5107-5114.
33. Maeshige N, Kitagawa K, Yamasaki S, Ishii A, Shirakawa T, Yang YM, Sung SY, Chen KC, Yuan ZM, Shigemura K, Fuhisawa M. Can Ultrasound irradiation be a therapeutic option for prostate cancer? Prostate 2020 Sep; 80(12): 986-992.
34. Tran HM, Wu KS, Sung SY, Changou CA, Hsieh TH, Liu YR, Liu YL, Tsai ML, Lee HL, Hsieh KLC, Huang WC, Liang ML, Chen HH, Lee YY, Lin SC, Ho DMT, Chang FC, Chao ME, Chen W, Chu SS, Yu ALT, Yen Y, Chang CC, Wong TT. Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. Cancers 2020, 12(3):E752 IF=6.162
35. Wu KS, Ho DMT, Jou ST, Yu AL, Tran HM, Liang ML, Chen HH, Lee YY, Chen YW, Lin SC, Chang FC, Tsai ML, Liu YL, Lee HL, Hsieh KLC, Huang WC, Sung SY, Chang CC, Cahngou CA, Liang KH, Hsieh TH, Liu YR, Chao ME, Chen W, Chu SS, Cho EC, and Wong TT. Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. Cancers 2020, 12(3):E653 IF=6.162
36. Shigemura K, Kitagawa K, Chen KC, Sung SY and Fujisawa M. Effect of preoperative dutasteride on holmium laser enucleation of the prostate. Urol. Int. 2020; 104(5-6):356-360. IF=1.271 (77.5%) 3x2x0.5=3
37. Shigemura K, Sung SY, Chen KC, Fujisawa M. Comment for “Nomogram establishment for surgery-related complication in partial nephrectomy”. Ann. Transl. Med. 2019 July, 7(supp 3): S120.
38. Sung SY* et al., A novel salicylanilide derivative induces autophagy cell death in castration-resistant Prostate Cancer via ER stress-activated PERK signaling pathway. Molecular Cancer Therapeutics, 2020 January, 19(1): 101-110
39. Katsumi Shigemura, Koichi Kitagawa, Sung SY, Chen KC, Masato Fujisawa. Retrospective study of current syphilis consultation in urologic clinics in Hyogo Prefecture, Japan. Infection, 2019, Accepted.
40. Chiang YT, Shigemura K, Nishimoto K, Sato K, Kitagawa K, Sung SY, Chen KC, Fujisawa M.Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: An international analysis. J. Int. Med. Res. 2019 Accepted.
41. Kitagawa K, Shigemura K, Sung SY, Chen KC, Huang CC, Chiang YT, Liu MC, Huang TW, Yamamichi F, Shirakawa T, Fujusawa M. Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression. J Cancer Research Clin. Oncol. 2019 Jul 31. (epub ahead of print).
42. WC Hsiao, SY Sung, Leland W.K. Chung, C.L. Hsieh., Osteonectin promoter-mediated suicide gene therapy of prostate cancer. Chapter 3, Suicide Gene Therapy: Methods and Protocols, Methods in Molecular Biology, Vol. 1895. 2019 Book
43. Chu GC, Chung LWK, Gururajan M, Hsieh CL, Josson S, Nandana S, Sung SY, Wang R, Wu JB, Zhau HE. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. Asian J. of Urology, 6: 65-81, 2019.
44. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Want WC, Chen HW, Kung HJ. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene, 38(1): 17-31, 2019
45. Y Lin, Sung SY*, Wu M*., et al., Effects of Cholesterol Levels on Mortality in Patients with Long-term Peritoneal Dialysis based on Residual Renal Function. Nutrients, 10(3): 300, 2018.
專書論文：
1. Raboshakga MO, Do AD, Kurniawati I, Hsieh CL, Sung SY*. Harnessing the Therapeutic Potential of Mesenchymal Stem Cells-derived Exosomes in Prostate Cancer: Current Insight and Perspective. Exosome Research – Biochemistry, Biomarkers and Perspective in Therapy (ISBN: 978-0-85466-989-9). London, United Kingdom: IntechOpen. Jan 2025.
2. Hsiao WC, Sung SY, Chung LWK, Hsieh CL. Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer. Methods Mol. Bio. (ISBN:978-1-4939-8922-5). New York, USA: Human Press. 2019: 1895:27-42.
研討會論文：
1. Do AD, Hsieh CL, Wong TT, Sung SY* (2024, Jun). Tumor-targeted extracellular vesicles carrying therapeutic siRNA to suppress metastasis in medulloblastoma. European Association for Cancer Research Annual Congress. Rotterdam, Netherlands. NSTC 112-2314-B-169-001.
2. Hsieh CL, Do AD, Sung SY* (2024, May). Development of an EV-based siRNA delivery platform for targeting metastatic cancer. International Society for Extracellular Vesicles Annual Meeting, Melbourne, Australia. NSTC112-2314-B-169-001.
3. Do AD, Hsieh CL, Wong TT, Sung SY*. (2023, Apr.). The Pro-metastatic role of long-noncoding RNA LOXL1-AS1 in sonic-hedgehog medulloblastoma. American Association for Cancer Research Annual Meeting, Orlando, USA. MOST110-2314-B-038-137-MY3.
4. Do AD, Hsieh CL, Wong TT, Sung SY*. (2022, Jun). LOXL1-AS1 contributes to medulloblastoma metastasis: A potential target for mesenchymal stem cell exosome-delivered gene therapy. American Association for Cancer Research, New Orleans, USA. MOST110-2314-B-038-137-MY3.
5. Hsieh CL, Huang HS, Chen KC, Saka T, Chiang CY, Sung SY*. (2019, Jul.) A novel salicylanilide derivative inhibits castration-resistant prostate cancer via endoplasmic reticulum stress-triggered PERK autophagic signaling pathway. AACR Annual Meeting, Atlanta GA.
